The future of RNA Tx is with Abzu.
Your partner for precise and exceptional results.
Abzu accelerates the development of new, innovative drugs with our proprietary explainable AI and expertise in RNA therapeutics.
Leading in short oligonucleotide innovation and design.
Precision therapeutics with ASOs, siRNAs, and antimiRs.
We’re redefining the potential of RNA therapeutics through our specialized workflow with ASOs, siRNAs, and antimiRs.
This focus ensures our therapeutics have high activity and exhibit minimal off-target effects, heralding a new era of precision medicine.
Abzu is your partner in RNA Tx design.
A cycle of innovation and optimization — to realization.
Whether we start with designs or your data, Abzu provides you the insights and confidence to accelerate your R&D and transform RNA Tx concepts into market-ready drugs.
Abzu’s measurable impact in RNA Tx design.
Where proven results speak louder than promises, Abzu stands apart.
Top-10 pharma result:
Top-10 pharma result:
Less data, more discovery.
Make the most out of every piece of information.
Contrary to the data-heavy demands of black-box AI, our technology thrives on minimal data. This efficiency not only accelerates the discovery process, but also reduces your barrier to entry to develop new, innovative drugs.
Benchmarks? We outperform them.
Our proprietary explainable AI outperforms in variance capture and sensitivity.
This benchmark from a real client case predicting molecule toxicity (using the same number of model features) is a testament to our proven team, technology, and results.
Our synergies can unlock the future of RNA Tx.
But first: Tell us about your scientific and business objectives.
Let’s have a conversation about your targets, therapies, and goals. If you share our vision for unlocking the future of RNA Tx with explainable AI, then please complete the form below to start the conversation.
Entering your information above does not subscribe you to marketing emails from Abzu. It just makes it easier for us to get in touch with you. If you want to subscribe for information from Abzu, you can subscribe here.